Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review

April 2021 | 61 pages | ID: A16EE7FD068EN
GlobalData

Abstracts

Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops and commercializes therapeutics based on RNAi interference. The company’s marketed RNAi therapeutics include, Onpattro, is used in treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for treatment of acute hepatic porphyria, Oxlumo developed for treatment of primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in the US, Austria, Belgium, Bermuda, Canada, France, Germany, Italy, Japan, Taiwan, Portugal, Spain, Sweden, the Netherlands, Switzerland, Czech Republic, and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Apr 15,2021: Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
Apr 06,2021: Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
Mar 11,2021: Alnylam issues inaugural corporate responsibility summary
Feb 18,2021: Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
Feb 11,2021: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Alnylam Pharmaceuticals Inc - Key Facts
Alnylam Pharmaceuticals Inc - Key Employees
Alnylam Pharmaceuticals Inc - Key Employee Biographies
Alnylam Pharmaceuticals Inc - Major Products and Services
Alnylam Pharmaceuticals Inc - History
Alnylam Pharmaceuticals Inc - Company Statement
Alnylam Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Alnylam Pharmaceuticals Inc - Business Description
Product Category: Product Revenue
Performance
Product Category: Revenue from Collaborations
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
R&D Overview
Alnylam Pharmaceuticals Inc - Corporate Strategy
Alnylam Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Alnylam Pharmaceuticals Inc - Strengths
Alnylam Pharmaceuticals Inc - Weaknesses
Alnylam Pharmaceuticals Inc - Opportunities
Alnylam Pharmaceuticals Inc - Threats
Alnylam Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 15, 2021: Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
Apr 06, 2021: Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
Mar 11, 2021: Alnylam issues inaugural corporate responsibility summary
Feb 18, 2021: Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
Feb 11, 2021: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
Jan 10, 2021: Alnylam launches “Alnylam P?x25” strategy for planned transition to a top five biotech in market capitalization over next five years
Dec 21, 2020: Alnylam appoints Tolga Tanguler chief commercial officer and also announces new CEMEA, medical affairs, and compliance leaders
Dec 15, 2020: Alnylam announces 2021 product and pipeline goals and provides program updates at R&D Day
Dec 08, 2020: CENTOGENE and Alnylam Pharmaceuticals launch a new clinical program aimed at revolutionizing the diagnosis of hereditary transthyretin-related amyloidosis (“ATTRv”)
Dec 07, 2020: Alnylam issues 2nd Annual Patient Access Philosophy report highlighting broad access to the company’s approved therapies

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Alnylam Pharmaceuticals Inc, Key Facts
Alnylam Pharmaceuticals Inc, Key Employees
Alnylam Pharmaceuticals Inc, Key Employee Biographies
Alnylam Pharmaceuticals Inc, Major Products and Services
Alnylam Pharmaceuticals Inc, History
Alnylam Pharmaceuticals Inc, Subsidiaries
Alnylam Pharmaceuticals Inc, Joint Venture
Alnylam Pharmaceuticals Inc, Key Competitors
Alnylam Pharmaceuticals Inc, Ratios based on current share price
Alnylam Pharmaceuticals Inc, Annual Ratios
Alnylam Pharmaceuticals Inc, Annual Ratios (Cont...1)
Alnylam Pharmaceuticals Inc, Interim Ratios
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Alnylam Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Alnylam Pharmaceuticals Inc, Ratio Charts
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021